S
Silvia Laura Bosello
Researcher at Catholic University of the Sacred Heart
Publications - 88
Citations - 2378
Silvia Laura Bosello is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 70 publications receiving 1983 citations. Previous affiliations of Silvia Laura Bosello include The Catholic University of America & Agostino Gemelli University Polyclinic.
Papers
More filters
Journal ArticleDOI
Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis
Giusy Peluso,Alessandro Michelutti,Silvia Laura Bosello,Elisa Gremese,Barbara Tolusso,Gianfranco Ferraccioli +5 more
TL;DR: Early disease seems to be the major determinant of full remission in rheumatoid arthritis, as well as possible predictors of US-PD remission, in patients with early RA (ERA) compared with longstanding RA (LSRA).
Journal ArticleDOI
B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
Silvia Laura Bosello,Maria De Santis,Gina Lama,Cristina Spano,Cristiana Angelucci,Barbara Tolusso,Gigliola Sica,Gianfranco Ferraccioli +7 more
TL;DR: Anti-CD20 treatment has been well tolerated and SSc patients experienced an improvement of the skin score and of clinical symptoms and the clear fall in IL-6 levels could contribute to the skin fibrosis improvement, while the presence of B cells in the skin seems to be irrelevant with respect to the outcome.
Journal ArticleDOI
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Silvia Laura Bosello,Giacomo De Luca,M. Rucco,G. Berardi,Matteo Falcione,Francesco Danza,Tommaso Pirronti,Gianfranco Ferraccioli +7 more
TL;DR: Anti-CD20 B cell depletion therapy is effective on skin involvement but seems also to preserve the pulmonary function, as supported by a stable or improved FVC and stable interstitial score, suggesting a possible role of rituximab as a modifying therapy overall in early diffuse SSc.
Journal Article
Concentrations of BAFF Correlate with Autoantibody Levels, Clinical Disease Activity, and Response to Treatment in Early Rheumatoid Arthritis
Silvia Laura Bosello,Pierre Youinou,Capucine Daridon,Barbara Tolusso,Boutahar Bendaoud,Donatello Pietrapertosa,Alessia Morelli,Gianfranco Ferraccioli +7 more
TL;DR: Elevated BAFF in a subset of ERA patients is related to autoantibody levels and synovitis, suggesting a rationale to treat ERA patients with BAFF-targeted agents.
Journal ArticleDOI
Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study.
Elisa Gremese,Fausto Salaffi,Silvia Laura Bosello,Alessandro Ciapetti,Francesca Bobbio-Pallavicini,Roberto Caporali,Gianfranco Ferraccioli +6 more
TL;DR: In a real-world setting, the 12 weeks disease duration and an early intervention with DMARD represent the most significant opportunities to reach the major outcome, ie, remission of RA.